AdvanCell’s abstract “Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TheraPb Trial “(2388P) has been accepted for presentation at ESMO 2025 (Berlin, 17-21 October).
The presentation will include clinical data from TheraPb Phase 1b dose Escalation of 212Pb-ADVC001 (NCT05720130). It marks a key milestone for AdvanCell and the Radioligand Therapy modality with the first ever 212Pb-PSMA clinical trial data being featured at a major clinical oncology conference.
